Pricing

  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.

Specifications

Panobinostat, a histone deacetylase inhibitor, is being tested in humans against cutaneous T cell lymphoma, prostate cancer, myelodysplastic syndromes, breast cancer, chronic myelogenous leukemia, and other types of malignant disease. Panobinostat inhibited histone deacetylase and induced acetylation of histone H3 and alpha-tubulin protein in human umbilical vein endothelial cells (HUVEC), which resulted in induction of G(2)-M cell cycle arrest and inhibition of HUVEC proliferation and viability. Panobinostat at noncytotoxic concentrations inhibited endothelial tube formation, Matrigel invasion, AKT activity, extracellular signal-regulated kinase 1/2 phosphorylation and chemokine receptor CXCR4 expression. It aslo reduced angiogenesis and PC-3 tumor growth in mice.
Catalog #	L1535
Solubility	Soluble in DMSO at 200mg/ml; soluble in ethanol at 5mg/ml with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50uM buffers, serum, or other additives may increase or decrease the aqueous solubility.
Melting Point	156-168ºC
Elemental Anaylsis	Calculated:
	C=70.09%
	H=6.77%
	N=11.68%
Storage and Stability	May be stored at RT for short-term only. Long-term storage is recommended at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
CAS Number	404950-80-7
Molecular Formula	C21H23N3O2
Molecular Weight	349.43
Purity	~99%
Form	Supplied as a white to off-white powder.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.